AU2021205326A1 - SMARCA2-VHL degraders - Google Patents

SMARCA2-VHL degraders Download PDF

Info

Publication number
AU2021205326A1
AU2021205326A1 AU2021205326A AU2021205326A AU2021205326A1 AU 2021205326 A1 AU2021205326 A1 AU 2021205326A1 AU 2021205326 A AU2021205326 A AU 2021205326A AU 2021205326 A AU2021205326 A AU 2021205326A AU 2021205326 A1 AU2021205326 A1 AU 2021205326A1
Authority
AU
Australia
Prior art keywords
compound
mmol
carcinomas
amino
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021205326A
Other languages
English (en)
Inventor
Abhisek Banerjee
Victor J. Cee
Ning Chen
Xiaofen Li
Ryan Paul Wurz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2021205326A1 publication Critical patent/AU2021205326A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021205326A 2020-01-10 2021-01-08 SMARCA2-VHL degraders Pending AU2021205326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959502P 2020-01-10 2020-01-10
US62/959,502 2020-01-10
PCT/US2021/012683 WO2021142247A1 (en) 2020-01-10 2021-01-08 Smarca2-vhl degraders

Publications (1)

Publication Number Publication Date
AU2021205326A1 true AU2021205326A1 (en) 2022-07-21

Family

ID=74495106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021205326A Pending AU2021205326A1 (en) 2020-01-10 2021-01-08 SMARCA2-VHL degraders

Country Status (7)

Country Link
US (1) US20230091042A1 (https=)
EP (1) EP4087658A1 (https=)
JP (1) JP7706456B2 (https=)
AU (1) AU2021205326A1 (https=)
CA (1) CA3167166A1 (https=)
MX (1) MX2022008487A (https=)
WO (1) WO2021142247A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
WO2022029617A1 (en) * 2020-08-04 2022-02-10 Aurigene Discovery Technologies Limited 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
EP4259144A4 (en) * 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
US11993599B2 (en) 2021-08-09 2024-05-28 Genentech, Inc. Therapeutic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
US20190300521A1 (en) * 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US12371426B2 (en) * 2018-04-26 2025-07-29 Aurigene Discovery Technologies Limited Pyridazine derivatives as SMARCA2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Also Published As

Publication number Publication date
MX2022008487A (es) 2022-08-02
US20230091042A1 (en) 2023-03-23
EP4087658A1 (en) 2022-11-16
WO2021142247A1 (en) 2021-07-15
JP2023510746A (ja) 2023-03-15
JP7706456B2 (ja) 2025-07-11
CA3167166A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
JP7706456B2 (ja) Ｓｍａｒｃａ２－ｖｈｌ分解剤
US10660888B2 (en) Aminoheteroaryl benzamides as kinase inhibitors
AU2018332887B2 (en) Bisamide sarcomere activating compounds and uses thereof
US11572374B2 (en) N-cyano-7-azanorbornane derivatives and uses thereof
CN114945566A (zh) 作为钠通道调节剂的取代四氢呋喃
JP6500024B2 (ja) Ｌｔａ４ｈ阻害剤としてのヘテロアリールブタン酸誘導体
TWI330176B (en) Inhibitor against the production and secretion of amyloid protein
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
WO2014020350A1 (en) Par2 receptor antagonists
CN104640843A (zh) 1-(环烷基羰基)脯氨酸衍生物
TW201139406A (en) Voltage-gated sodium channel blockers
CZ301631B6 (cs) Ortho- a meta-substituované bisarylové slouceniny a farmaceutické prostredky, které je obsahují
TW201348239A (zh) 環狀橋頭醚ｄｇａｔ１抑制劑
AU2014274354A1 (en) Dihydropyridinone MGAT2 inhibitors
JP7726591B2 (ja) ボロン酸化合物
AU2012279091A1 (en) Voltage-gated sodium channel blockers
JP2021530532A (ja) Ｔｒｋ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体
TW202342060A (zh) Ｌｏｎｐ１抑制劑化合物、用途及方法
TWI670262B (zh) 新穎雜芳基丁酸衍生物
JP2024521868A (ja) ＸＩＩａ因子阻害剤